Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

What Was Tested

In this phase 3 trial, researchers set out to test MariTide (Maridebart Cafraglutide).

It had 1 arm (groups): Maridebart cafraglutide (experimental).

The registry classes the interventions as device and drug.

Who Took Part

230 planned participants were the target.

It was open to people of any sex aged from 18 years up to 99 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Body mass index (BMI) ≥ 30 kilograms per meter square (kg/m\^2), or BMI ≥ 27 to \< 30 kg/m\^2 with one of the following:. Hypertension: treated, or with systolic blood pressure ≥ 130 millimeters of mercury (mmHg) or diastolic blood pressure ≥ 80 mmHg. Dyslipidemia: treated or previously diagnosed high cholesterol, high triglycerides, or low HDL cholesterol. History of obstructive sleep apnea. History of cardiovascular disease.

The full record lists 9 inclusion and 8 exclusion criteria; among the exclusions: obesity induced by other endocrinologic disorders; change in body weight \> 5 kg within last 90 days; previous or planned surgical, endoscopic, or device-based treatment for obesity.

How the Study Was Run

Design: single-group and open-label.

Nothing was hidden in this open-label MariTide (Maridebart Cafraglutide) study: the participants and staff both knew the treatment.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-10-28 with completion listed for 2027-06-16.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 4 secondary outcomes, for example Number of Participants Who Experience Device-related Adverse Events, Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Plasma Concentration of Maridebart Cafraglutide at Week 24 and Percent Change From Baseline in Body Weight at Week 24.

What This Means in Plain Language

Put simply, this is a phase 3 trial of MariTide (Maridebart Cafraglutide) in 230 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the MariTide (Maridebart Cafraglutide) compound page, all human trials.